Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * Decheng Capital Global Life Sciences Fund IV, L.P.	2. Date of Event Requiring Statement (MM/DD/YYYY) 2/5/2021	3. Issuer Name and Ticker or Trading Symbol Equillium, Inc. [EQ]
(Last)        (First)        (Middle) UGLAND HOUSE, P.O. BOX 309	4. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director                          ___X___ 10% Owner _____ Officer (give title below)        _____ Other (specify below)
(Street) GRAND CAYMAN, E9 KY1-1104       (City)              (State)              (Zip)	5. If Amendment, Date Original Filed(MM/DD/YYYY)	6. Individual or Joint/Group Filing(Check Applicable Line) ___ Form filed by One Reporting Person _X_ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock (1)	3285710	I	See Footnote (2)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrant (right to buy) (1)	2/5/2021	2/5/2026	Common Stock	985713	$14.00	I	See Footnote (2)

Explanation of Responses:
(1)	The reportable securities are included within 3,285,710 units representing (i) 3,285,710 shares of the Company's common stock, par value $0.0001 per share ("Common Stock"), and (ii) warrants to purchase an additional 985,713 shares of Common Stock for $7.00 per unit (each unit consisting of one share of Common Stock and a warrant to purchase 0.3 of a share of Common Stock).
(2)	The reportable securities are held directly by Decheng Capital Global Life Sciences Fund IV, L.P. (the "Fund"). Decheng Capital Management IV (Cayman), LLC (the "GP") is the general partner of the Fund. Xiangmin Cui is the manager of the GP. Each of the Fund, the GP and Dr. Cui may be deemed to beneficially own the securities held by the Fund. Each of the Fund, the GP and Dr. Cui disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Decheng Capital Global Life Sciences Fund IV, L.P. UGLAND HOUSE, P.O. BOX 309 GRAND CAYMAN, E9 KY1-1104		X
Decheng Capital Management IV (Cayman), LLC UGLAND HOUSE, P.O .BOX 309 GRAND CAYMAN, E9 KY1-1104		X
Cui Xiangmin UGLAND HOUSE, P.O .BOX 309 GRAND CAYMAN, E9 KY1-1104		X

Signatures
/s/ Xiangmin Cui		2/15/2021
**Signature of Reporting Person		Date
/s/ Xiangmin Cui		2/15/2021
**Signature of Reporting Person		Date
/s/ Xiangmin Cui		2/15/2021
**Signature of Reporting Person		Date